Form 4: Vistagen Therapeutics Chief Legal Officer Acquires Shares Through Employee Stock Purchase Plan

Vistagen Therapeutics' Chief Legal Officer, Reid G. Adler, acquired 7,541 shares of common stock at $1.70 per share through the company's Employee Stock Purchase Plan.

Summary

• Reid G. Adler, the Chief Legal Officer of Vistagen Therapeutics, Inc. (VTGN), acquired common stock.
• The transaction occurred on June 30, 2025.
• A total of 7,541 shares of common stock were acquired.
• The acquisition price was $1.70 per share.
• Following this transaction, Reid G. Adler beneficially owns 24,050 shares of common stock.
• The shares were acquired under the Issuer's 2019 Employee Stock Purchase Plan, as amended.
• The transaction is exempt under SEC Rule 16b-3(c) and Rule 16b-3(d).

Sentiment

Score: 7

Explanation: The acquisition of shares by a key executive, particularly through an employee stock purchase plan, generally signals confidence in the company's future performance and is a positive indicator.

Positives

• Chief Legal Officer Reid G. Adler acquired 7,541 shares of Vistagen Therapeutics common stock, which can be interpreted as a signal of insider confidence in the company's future.
• The acquisition was made through the company's Employee Stock Purchase Plan, indicating participation in employee benefit programs and alignment of interests with shareholders.

Future Outlook

NA

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: May perceive the insider acquisition as a positive indicator of management's confidence in the company's stock performance.
• Employees: The transaction highlights the utilization of the company's Employee Stock Purchase Plan, which is a benefit available to eligible employees.

Key Dates

Recommendation

Keywords

Vistagen Therapeutics, VTGN, Reid G. Adler, Chief Legal Officer, insider transaction, stock acquisition, employee stock purchase plan, ESPP, SEC Form 4